These proposed and developing targeted therapeutic strategies, particularly in cardiac dysfunction, cancer, and diabetes/obesity, require consideration and a deep understanding of Pak1 in relation to off‐target effects. This evidence concerns the gene PAK1 and diabetes mellitus.